Dr. Mike Murray's work is focused on understanding the value of using DNA-based screening of populations in order to identify those individuals with a cancer and heart disease risk for which preventive-care interventions are available. He joined Yale in 2018 as the director of clinical operations in the newly formed Yale Center of Genomic Health.

In 2019 he led the launch of "Generations", a population health project that will enroll at least 100,000 volunteers. This project links genomic data with electronic health data in order to enable both research and patient care delivery.

From 2013 to 2018 he was the Geisinger Health System's first director of clinical genomics. At Geisinger he led the design and implementation of the GenomeFIRST program in 2015. GenomeFIRST delivered risk results regarding cancer and heart disease to patients and their healthcare providers, and then guided their clinical management in ongoing screening and prevention.

Prior to his time at Geisinger he was on the faculty at Harvard Medical School and was the clinical chief of genetics at Brigham and Women's Hospital in Boston for nine years. He is a physician and is board certified in Internal Medicine and Medical Genetics.

He is currently a member of the ACMG Board of Directors, and serves on the 54gene scientific advisory board.